Oncolytic adenovirus vaccine(Targovax/Valo Therapeutics)

N/A

Report date: 2023/12/01 16:57:18

Base Information

Drug NameOncolytic adenovirus vaccine(Targovax/Valo Therapeutics)
Drug Alias NameRAS-targeting oncolytic adenovirus vaccine(Targovax/Valo Therapeutics)RAS-targeting ONCOS vaccine(Targovax/Valo Therapeutics)
ClassificationBiologics > Oncolytic virusVaccines > Biological material > Viral vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsRAS gene modulators
TargetsNot applicable
Therapy Area/IndicationsPancreatic NeoplasmsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorway
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTargovax
China Registration ClassN/A

Develop Information

Active CompaniesValo Therapeutics OyTargovax
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsMultiple Myeloma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A